Rybelsus (Semaglutide)

Rybelsus tablets (semaglutide) are used for adults with type 2 diabetes mellitus to control blood sugar levels. Rybelsus has also been shown in studies to help weight loss, but it is not an FDA-approved weight loss medicine. Rybelsus tablets are a once-a-day tablet that is used along with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonist).

Rybelsus tablets contain the same active ingredient as Wegovy injection and Ozempic injection. Wegovy is approved for weight management, and Ozempic is approved for type 2 diabetes.

Rybelsus is not for treating type 1 diabetes.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.

Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.